Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunoglobulin G pegylated - Mitsubishi Tanabe Pharma

Next Previous
Drug Profile

Immunoglobulin G pegylated - Mitsubishi Tanabe Pharma

Alternative Names: GB-0998; Human immunoglobulin G - Mitsubishi Tanabe Pharma; Immunoglobulin intravenous - Mitsubishi Tanabe Pharma; Intravenous immunoglobulin - Mitsubishi Tanabe Pharma; Kenketsu Venoglobulin-IH; Polyethylene glycol treated human normal immunoglobulin; Venoglobulin IH

Latest Information Update: 19 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Japan Blood Products Organization; Mitsubishi Tanabe Pharma Corporation
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection; Myasthenia gravis; Dermatomyositis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Agammaglobulinaemia; Bacterial infections; Bronchitis; Dermatomyositis; Myasthenia gravis; Otitis; Pneumonia; Polymyositis
  • Registered Transplant rejection
  • Phase III Spontaneous abortion
  • Discontinued Guillain-Barre syndrome; Immunodeficiency disorders; Systemic scleroderma

Most Recent Events

  • 19 Nov 2021 Japan Blood Products Organization completes a phase III trial in Spontaneous abortion (Recurrent) in Japan (IV) (NCT02184741)
  • 12 Nov 2021 Phase-III clinical trials in Spontaneous abortion (Recurrent) in Japan (IV) (NCT02184741)
  • 22 Feb 2021 Discontinued - Phase-III for Guillain-Barre syndrome in Japan (IV) (Mitsubishi Tanabe Pharma's pipeline, February 2021) (Japan Blood Products Organization's pipeline, February 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top